https://www.selleckchem.com/products/abbv-744.html
This study presents a meaningful and distinctive attempt of a new approach for the design and development of MOC-based heterogeneous photocatalysts.This phase 1, 2-part, 2-period, open-label, drug-drug interaction study evaluated the potential for pharmacokinetic interactions between upadacitinib and rosuvastatin, an organic anion transporting polypeptide (OATP) 1B1 and breast cancer resistance protein substrate, or atorvastatin, a cytochrome P450 3A, OATP1B1, and OATP1B3 substrate, in 36 healthy volunteers. During period 1, a single d
Like
Comment
Share
